COVID-19 infections increased risk of heart conditions
On Feb. 7, 2022, researchers at Washington University School of Medicine in St. Louis announced an analysis of…
Research collaboration launched to focus on repurposing existing anti-viral therapies to treat COVID-19
On Feb. 4, 2022, a new ï¾£1.6m collaborative project was launched to rapidly identify new treatments for COVID-19….
How sneezing hamsters sparked a COVID outbreak in Hong Kong
On Feb. 4, 2022, pet hamsters probably carried the Delta variant of SARS-CoV-2 into Hong Kong and sparked…
CDC’s ACIP issued recommendation for use of Moderna COVID-19 vaccine in adults aged =18 years
On Feb. 4, 2022, the Advisory Committee on Immunization Practices (ACIP) issued a standard recommendation for use of…
UK MHRA granted Conditional Marketing Authorization for Novavax COVID-19 vaccine in Great Britain
On Feb. 3, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency had granted conditional marketing…
T2 Biosystems T2SARS-CoV-2 panel detects Omicron subvariants
On Feb. 3, 2022, T2 Biosystems announced that its T2SARS-CoV-2 Panel detected Omicron COVID-19 subvariants BA.1, BA.2, and…
New Zealand’s Medsafe granted provisional approval for Novavax’ COVID-19 vaccine
On Feb. 3, 2022, Novavax announced that New Zealand’s Medsafe had been granted provisional approval of NVX-CoV2373, Novavax’…
NIAID Pandemic Preparedness Plan targeted ‘prototype’ and priority pathogens
On Feb. 2, 2022, NIAID scientists announced the new Pandemic Preparedness Plan aimed to support critical basic and…
Pfizer and BioNTech initiated rolling submission for EUA of COVID-19 vaccine in children 6 months through 4 years of age
On Feb. 1, 2022, Pfizer and BioNTech announced that following a request from the U.S. Food and Drug…
Moderna received full U.S. FDA approval for COVID-19 vaccine Spikevax
On Jan. 31, 2022, Moderna announced the U.S. Food and Drug Administration (FDA)Â had approved the Biologics License…
Novavax submitted request to U.S. FDA for Emergency Use Authorization of COVID-19 vaccine
On Jan. 31, 2022, Novavax announced that it had submitted a request to the U.S Food and Drug…
InteliSwabï¾® COVID-19 rapid tests receive U.S. FDA authorization for pediatric use
On Jan. 31, 2022, OraSure Technologies announced that its InteliSwabï¾® COVID-19 rapid tests had been authorized by the…
Veru announced FDA Grant of Fast Track Designation for Sabizabulin for treatment of hospitalized COVID-19 patients
On Jan. 31, 2022, Veru announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track…
Novavax and Israel announced advance purchase agreement for supply of COVID-19 vaccine
On Jan. 28, 2022, Novavax and Israel’s Ministry of Health announced an agreement for the purchase of NVX-CoV2373,…
WHO and Viamo provided critical access to COVID-19 information to the next billion digital users via their mobile phones
On Jan. 28, 2022, the WHO announced that COVID-19 information had reached 1,292,209 people through Viamoï¾’s 3-2-1 Platform…
Merck and Ridgeback’s Molnupiravir, investigational antiviral COVID-19 medicine, demonstrated activity against Omicron variant
On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…
Cocrystal Pharma selected two lead antiviral drug candidates for COVID-19 oral drug program
On Jan. 27, 2022, Cocrystal Pharma announced that it had selected two investigational novel antiviral drug candidates for…
Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19
On Jan. 27, 2022, NIAID announced that a clinical trial found that the combination of remdesivir plus a…
Moderna announced first participant dosed in phase 2 study of Omicron-specific booster candidate and publication of data
On Jan. 26, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
COVID-19 | FDA | Life Science History | NIH
Mix-and-match trial found additional dose of COVID-19 vaccine safe, immunogenic
On Jan. 26, 2022, the NIH announced that adults who had previously received a full regimen of any…
Pfizer and BioNTech initiated study to evaluate Omicron-based COVID-19 vaccine in adults 18 to 55 years of age
On Jan. 25, 2022, Pfizer and BioNTech announced the initiation of a clinical study to evaluate the safety,…
University of Missouri researchers identified mutations of Delta, Delta Plus variants
On Jan. 25, 2022, researchers at the University of Missouri announced they had identified the highly prevalent, specific…
Cepheid received Health Canada license for Xpert Xpress CoV-2/Flu/RSV plus
On Jan, 25, 2022, Cepheid announced that Health Canada had issued Cepheid a medical device license for Xpert…
Pfizer and BioNTech published data from two studies on COVID-19 vaccine-induced antibodies ability to neutralize SARS-CoV-2 Omicron variant
On Jan. 24, 2022, Pfizer and BioNTech announced the publication of new results from two laboratory studies demonstrating…
Anixa Biosciences and MolGenie announced early potency analysis of SARS-CoV-2 protease inhibitor
On Jan. 24, 2022, Anixa Biosciences announced that the company and its partner, MolGenie, had synthesized a compound…
‘Ultrapotent’ antibodies neutralized SARS-CoV-2 variants in NIAID study
On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they…
FDA approved Veklury (Remdesivir) for treatment of non-hospitalized patients at high risk for COVID-19 disease progression
On Jan. 20, 2022, Gilead Sciences announced that the U.S. Food and Drug Administration had granted expedited approval…
Australia Therapeutic Goods Administration granted provisional registration for Novavax COVID-19 vaccine
On Jan. 19, 2022, Novavaxa announced that Australia’s Therapeutic Goods Administration had granted approval for provisional registration of…
Brazilian Health Regulatory Agency authorized Sorrento phase 2 clinical trial of COVI-MSC in COVID-19l long-hauler patients
On Jan. 18, 2022, Sorrento Therapeutics announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed…
Merck and Ridgeback announced supply agreement with UNICEF for molnupiravir, investigational oral antiviral COVID-19 medicine
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…